← All trials
NCT05329220
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2022
- Primary completion
- Dec 31, 2022
- Completion date
- May 31, 2023
- First posted
- Apr 14, 2022
- Last posted
- Nov 28, 2022
- Enrollment
- 4000
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Bavarian NordicLead sponsor
- Bavarian NordicStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.